|
3M submitted a supplemental report to the EPA regarding a pharmacokinetic study on ammonium perfluorooctanoate (PFOA) in rats, following previous communications about related reproductive studies.
|
2004 |
AR226-1550
|
DDgRMBzvyd5wYXQBaL55nzxnM |
1 |
|
3M submitted a supplemental report to the EPA detailing results from a study on ammonium perfluorooctanoate (PFOA) regarding its effects on plasma concentration in post-weaning rats following oral gavage.
|
2004 |
AR226-1552
|
RJ6J9eOGy2g1Lvvv3yQqBKKzX |
1 |
|
3M submitted a supplemental report to the EPA detailing a pharmacokinetic study that found perfluorooctanesulfonyl fluoride (POSF) metabolizes to perfluorooctane sulfonate (PFOS) in rats, with maximum PFOS concentration observed in the liver on day 4 post-dose.
|
2004 |
AR226-1694
|
ByVvDBNOBXmJQV9VGEM431D94 |
1 |
|
The document is a correspondence from Taft, Stettinius & Hollister LLP regarding a PFOA human health effects study, specifically addressing cancer data related to PFOA.
|
2004 |
AR226-1714
|
6R2vYY98bVJ4deOag9zQvRwR1 |
1 |
|
The document is a submission of a study report on the biodegradation of 14C-labeled 8-2 Telomer B Alcohol by the Telomer Research Program, which includes companies like DuPont and Daikin Industries, to the EPA for inclusion in the administrative record, with a request for the report to be restricted to "read-only" status until a related manuscript is published.
|
2003 |
AR226-1639
|
VKOn56XVxvEow8RMV33r5Xwdj |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program, including member companies such as DuPont, to the EPA, providing a study report on the ecotoxicity of C8-2 alcohol based on a 21-day Daphnia magna reproduction test.
|
2003 |
AR226-1642
|
b5JNVLmO1RXjzz2pRKy6x3JOo |
1 |
|
The document presents blood data from 2001 for DuPont employees, including levels of perfluorinated compounds, with specific results for Granular Polykettle Operators and Fine Powder/Dispersion Autoclave Operators, while maintaining employee confidentiality.
|
2002 |
AR226-1638
|
aBMx5NZN3R9OmXL77JNg0BYv9 |
1 |
|
The document discusses changes in the environmental hazard narrative for PFOA, noting a reduction in the Margin of Exposure (MOE) from 300 to 1000, which results in a new drinking water guideline of 10 ug/L, lower than the previously communicated 14 ug/L, prompting the need for clarification to the EPA regarding this discrepancy.
|
2002 |
AR226-1690
|
2qvKk23KKe602yVvQRe7xaOea |
1 |
|
The document discusses the sharing of a draft monograph related to PFOA by DuPont with regulatory agencies, highlighting the company's conservative approach in setting its CEG and addressing concerns about potential FOIA requests.
|
2002 |
AR226-1691
|
vp1ReVp0QBaQV4KQGx14jJXE |
1 |
|
The document describes the ongoing RCRA interim remedial measures program at the 3M Decatur site, focusing on the construction of a containment structure for an inactive landfill to mitigate groundwater contamination, with key components including a subsurface sheet-piling barrier and an upgrade to a multilayer cap to prevent precipitation infiltration.
|
2002 |
AR226-1700
|
1QnQpwmpOJ8MobDGn9EdBmnkm |
1 |
|
The document is a letter from the EPA to DuPont Haskell Laboratory requesting clarification on why results related to ammonium perfluorooctanoate (PFOA) were submitted as voluntary rather than under TSCA Section 8(e), given the potential human health hazard concerns indicated by human blood serum tests.
|
2001 |
AR226-1557
|
vB36dMw4V0ZqMBrnO340apVqm |
1 |
|
The document is a letter from the EPA requesting DuPont Haskell Laboratory to provide the complete data set of blood concentrations related to Ammonium Perfluorooctanoate (AFPO) as summarized in their report, following a previous inquiry.
|
2001 |
AR226-1559
|
pXoLYjyrknaBEV7YgwBJ2zD6 |
1 |
|
The document discusses concerns raised by an engineer regarding the poor recovery rate (25%) of the analytical technique used for measuring surfactants, including PFOA, at Parkersburg, which may lead to previously reported results being significantly underestimated and potentially exceeding the safe drinking water level of 1 ppb.
|
2001 |
AR226-1677
|
B8Z0e9B6Z87wL8d1vxn22kQ6m |
1 |
|
DuPont expresses concerns about potential increases in PFOA levels above the company's conservative exposure guideline of 1 ppb due to new analytical techniques, and plans to discuss these concerns with EPA Region 3 to avoid mandatory provision of alternative drinking water.
|
2001 |
AR226-1680
|
5LBn0ZwnDY7Rz0qwG6KbqLnb4 |
1 |
|
The document discusses a request from DuPont representatives to meet with EPA Region 3 to express concerns about the use of their CEG as a screening level for health risks related to PFOA, while also planning to present a new analytical method and sampling protocol.
|
2001 |
AR226-1681
|
3N673kVDNOn3xLVMYjnVOD8b3 |
1 |
|
Unreadable document.
|
2001 |
AR226-1683
|
3NEVJLgo8RXvoOzELKr7kNj8y |
1 |
|
The document discusses a communication regarding the assessment of chronic versus acute exposures to PFOA, highlighting a disagreement with the West Virginia Department of Environmental Protection regarding focus on annual average concentrations in the community versus short-term exposure limits.
|
2001 |
AR226-1684
|
DvxRpB5RXZq7zdyYxqnVYeQjd |
1 |
|
The document discusses an upcoming meeting regarding new drinking water concentration testing for PFOA, indicating expectations of significantly higher readings than previously reported, and the need to manage communication with regulators to avoid panic over potential contamination.
|
2001 |
AR226-1685
|
re4dDQOvvXYv9BOKk4zRB7wVv |
1 |
|
The document discusses a meeting with EPA Region 3 regarding PFOA, highlighting the need for updated primate study results, air monitoring data from DuPont, and the implications of new analytical protocols on PFOA serum and water concentration measurements.
|
2001 |
AR226-1686
|
x5Dy55q24pL1kRx4wjRp5YrR6 |
1 |
|
The document discusses a communication from Jack S. Mandel regarding his potential collaboration with DuPont on PFOA-related issues, indicating that 3M has no objection to his involvement as long as confidentiality is maintained between the two companies.
|
2001 |
AR226-1688
|
RJKbNjejkJ9nV8x2EDR2rZnB |
1 |
|
DuPont is seeking expert assistance to defend against a lawsuit from a farmer in West Virginia alleging health and environmental impacts related to PFOA from a non-hazardous landfill, despite their assessment indicating negligible risks to the farmer's cattle.
|
2000 |
AR226-1676
|
50bvY96NmMJMZva24yj9b9ww8 |
1 |
|
This is a cover page from Pace Analytical Services, Inc. for the 3M Multi-city Food Study, prepared under contract with 3M for project number E00-2789.
|
2000 |
AR226-1698
|
Xw1z0wxVvJ2BxokoNb49x6qK |
1 |
|
The document discusses a meeting scheduled for December 6, 1996, involving Rik Brandenburg and representatives from Hoechst and ICI to collaborate on analytical methods for determining the migration of C-8 (PFOA) from PTFE coated pans into food simulants, addressing the need for a reliable method for migration into olive oil.
|
1996 |
AR226-1665
|
6beBJwekkNpQbz8bkNK7KVjgo |
1 |
|
The document is a request from DuPont to establish acceptable levels for ammonium perfluorooctanoate (C-8) in blood and community drinking water.
|
1987 |
AR226-1636
|
emd9Bw5dVV5zwdYLqRng6nKdq |
1 |
|
The document is a recommendation from Bruce W. Karrh, M.D. of DuPont to proceed with blood tests for FC-143 (a perfluorinated compound) on employees involved in Teflon production, indicating that further testing may not be necessary after initial analyses.
|
1983 |
AR226-1626
|
3J5jj850zyL3DYjdO38ZDm743 |
1 |
|
This document outlines the findings of organic fluoride levels in the blood of Experimental Station employees, linked to by-products of HFPO synthesis, and details a program to investigate health impacts and implement further testing and communication with affected employees.
|
1982 |
AR226-1615
|
Yj2dyqQye0aQR09Bg50XNm8Zy |
1 |
|
The document discusses the recommendation for periodic blood tests for employees potentially exposed to FC-143 (a perfluorinated compound) to monitor their blood concentration levels, noting that "Teflon" operators have shown relatively low exposure levels.
|
1982 |
AR226-1613
|
b5E1zpEQp4xkwwv6E6VQbkdv6 |
1 |
|
The document discusses the decision not to pursue a program for achieving a C-8 material balance for TEFLON employees due to recent findings on C-8 embryotoxicity and declining blood levels, while supporting additional blood sampling for certain employees and emphasizing the need for a detailed epidemiological study to determine safe blood levels of C-8.
|
1982 |
AR226-1620
|
1Q0q3EGrVKwKnB3n6pmY0LGYX |
1 |
|
The document outlines a plan to reduce the blood sampling program for C-8 (perfluorooctanoic acid, PFOA) at DuPont and 3M, stating that no adverse health effects have been detected at current levels, while continuing to monitor specific personnel with potential exposure.
|
1982 |
AR226-1616
|
6M8dK4bQ0vRXm8ragDBy3Mmg |
1 |
|
The document discusses a request for increased blood sampling frequency for retired male employees and those transferred from the Fluoropolymers Division to gather more data on C-8 (PFOA) elimination rates, due to previously low participation in the program.
|
1982 |
AR226-1621
|
mkmbe8NXDxJ0ad4doNvOovQk |
1 |
|
The document discusses the inadequacy of current data on C-8 (PFOA) blood levels and elimination rates among employees at the Teflon Polymer Division, emphasizing the need for accurate monitoring of individuals no longer exposed to C-8 to assess long-term health implications.
|
1982 |
AR226-1624
|
yqJnj7wLwDYM67Bypzpnqja2 |
1 |
|
This memo from DuPont discusses a change in the analytical test method for measuring C-8 (PFOA) in blood samples of personnel, indicating that the new gas chromatography method provides results approximately 282% higher than the previous method.
|
1981 |
AR226-1565
|
LK6obJzvEzV5R1ENyZ8o1ZrLb |
1 |
|
The document outlines a blood sampling program for employees exposed to C-8 (PFOA) to analyze organic fluorine levels and determine the elimination rate of C-8 from the body, specifically targeting female employees who have worked with TEFLON.
|
1981 |
AR226-1563
|
4J22VXEenbq6kjK904p71zRnx |
1 |
|
The document discusses ongoing blood level testing for C-8 (perfluorooctanoic acid, PFOA) among exposed employees and controls, noting that controls have shown non-detectable levels, while an animal study has been initiated to determine a "no-effect" level in rats.
|
1981 |
AR226-1568
|
mBL6Lje3rm7QL1jEqXyjxxrXb |
1 |
|
The document reports the analysis of a blood sample for perfluorooctanoate (PFOA) conducted by DuPont, revealing a concentration of 0.17 ppm F, with details on the analytical method and precision.
|
1981 |
AR226-1592
|
gDagROd5yZypx1eEk3jQ26dXL |
1 |
|
The document presents analytical results for FC-143 (Ammonium Perfluorooctanoate) in blood samples from polymer product workers at Chambers Works, indicating a range of concentrations from 0 to 0.250 with an overall mean of 0.049.
|
1981 |
AR226-1597
|
6wEZ618kJY3XxbKDj0r0Zz0vd |
1 |
|
This is a laboratory report prepared for John Bowman on May 17, 2001, detailing comparison results for PFNA relative percent recovery in various samples.
|
— |
AR226-1678
|
2qMRDa5jqV80Jqpg18Q9qv8Ra |
2 |
|
Unreadable document.
|
— |
AR226-1687
|
RpV2eMj5MMvnx3MaVaB5O2yM8 |
1 |
|
The document reports on a study examining cancer prevalence among subjects exposed to perfluorooctanoic acid (PFOA) near a manufacturing plant, finding elevated cancer rates, particularly for prostate, cervical, and uterine cancers, compared to the general population.
|
— |
AR226-1716
|
znLZrvD08x71ER6gJKq3QGnB |
1 |
|
This document reports on a study investigating the potential interference of perfluorooctane sulfonic acid potassium salt with cholesterol measurements in rat serum, detailing the methodology and cholesterol concentration results.
|
— |
AR226-1726
|
MGogGBQo08Ox57B9xvaO0ynwx |
1 |
|
This is an aquatic toxicity data sheet from the Environmental Engineering Laboratory detailing a test on a material with various parameters including organism exposure, dilution water characteristics, and observed mortality rates over multiple time intervals.
|
— |
AR226-1756
|
EKDYpmrYj1Z4wk9wLzNxRzK0 |
1 |
|
The document presents ecotoxicological testing results for PFOS, detailing various effect concentrations and no-observed effect concentrations (NOEC) across multiple aquatic and avian species, indicating significant inhibition and toxicity at high concentrations.
|
— |
AR226-1757
|
X7GDEY9Jaxzq8VYV5pJ131jB |
1 |